{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:14:25Z","timestamp":1791825265638,"version":"4.3.4"},"reference-count":94,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,3,15]]},"DOI":"10.3233\/jad-150493","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T14:05:32Z","timestamp":1458137132000},"page":"501-514","source":"Crossref","is-referenced-by-count":268,"title":["Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial"],"prefix":"10.1177","volume":"51","author":[{"given":"Jos\u00e9 A.","family":"Luchsinger","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, NY, USA"},{"name":"Department of Epidemiology, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thania","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Statistics, Mt. Sinai Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Mehta","sequence":"additional","affiliation":[{"name":"New York Institute for Basic Research, Staten Island, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Steffener","sequence":"additional","affiliation":[{"name":"Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnanavalli","family":"Pradabhan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Medical Center, New York, NY, USA"},{"name":"Department of Radiology, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ichise","sequence":"additional","affiliation":[{"name":"Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Manly","sequence":"additional","affiliation":[{"name":"Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davangere P.","family":"Devanand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Medical Center, New York, NY, USA"},{"name":"Department of Radiology, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Bagiella","sequence":"additional","affiliation":[{"name":"Department of Statistics, Mt. Sinai Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-150493_ref1","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.jalz.2014.02.001","article-title":"2014 Alzheimer\u2019s disease facts and figures","volume":"10","author":"Alzheimer\u2019s, Association","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-150493_ref2","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1001\/jama.1989.03430180093036","article-title":"Prevalence of Alzheimer\u2019s disease in a community population of older persons. Higher than previously reported","volume":"262","author":"Evans","year":"1989","journal-title":"JAMA"},{"key":"10.3233\/JAD-150493_ref3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"10.3233\/JAD-150493_ref4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.283.12.1615","article-title":"The origins of Alzheimer disease: A is for amyloid","volume":"283","author":"Selkoe","year":"2000","journal-title":"JAMA"},{"key":"10.3233\/JAD-150493_ref5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.1997.03540340047031","article-title":"Brain infarction and the clinical expression of Alzheimer disease. The Nun Study","volume":"277","author":"Snowdon","year":"1997","journal-title":"JAMA"},{"key":"10.3233\/JAD-150493_ref6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archneurol.2009.266","article-title":"Mild cognitive impairment: Ten years later","volume":"66","author":"Petersen","year":"2009","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJMra040223","article-title":"Alzheimer\u2019s disease","volume":"351","author":"Cummings","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMe1313943","article-title":"Anti-amyloid therapy for Alzheimer\u2019s disease\u2013are we on the right road?","volume":"370","author":"Karran","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref9","unstructured":"(2010) NIH consensus development conference statement on preventing Alzheimer\u2019s disease and cognitive decline. NIH Consensus and State-of-the-Art Statements, volume 27, number 4."},{"key":"10.3233\/JAD-150493_ref10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-642-04300-0_7","volume-title":"Diabetes, Insulin, and Alzheimer\u2019s Disease","author":"Luchsinger","year":"2010"},{"key":"10.3233\/JAD-150493_ref11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-2010-091687","article-title":"Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?","volume":"20","author":"Luchsinger","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-150493_ref12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","article-title":"Prevalence and trends in obesity among US adults, 1999-2008","volume":"303","author":"Flegal","year":"2010","journal-title":"JAMA"},{"key":"10.3233\/JAD-150493_ref13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999-2004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA"},{"key":"10.3233\/JAD-150493_ref14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archneur.64.4.570","article-title":"Relation of Diabetes to Mild Cognitive Impairment","volume":"64","author":"Luchsinger","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref15","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/archneur.64.12.1734","article-title":"Hypertension and the risk of mild cognitive impairment","volume":"64","author":"Reitz","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref17","first-page":"17","article-title":"Should we target insulin resistance to prevent dementia due to Alzheimer disease?","volume":"68","author":"Luchsinger","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2337\/dc07-0797","article-title":"Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: Findings from the Northern Manhattan Study (NOMAS)","volume":"31","author":"Boden-Albala","year":"2008","journal-title":"Diabetes Care"},{"key":"10.3233\/JAD-150493_ref19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1212\/01.WNL.0000055863.87435.B2","article-title":"Relation of cerebral infarctions to dementia and cognitive function in older persons","volume":"60","author":"Schneider","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1212\/01.WNL.0000118211.78503.F5","article-title":"Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology","volume":"62","author":"Schneider","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling older persons","volume":"69","author":"Schneider","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/156720507780362137","article-title":"Insulin resistance and Alzheimer\u2019s disease pathogenesis: Potential mechanisms and implications for treatment","volume":"4","author":"Craft","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-150493_ref23","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","article-title":"Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of lifestyle intervention and metformin","volume":"54","author":"The Diabetes Prevention Program Research G","year":"2005","journal-title":"Diabetes"},{"key":"10.3233\/JAD-150493_ref24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMcibr1409796","article-title":"The target of metformin in type 2 diabetes","volume":"371","author":"Ferrannini","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/01.WNL.0000140292.04932.87","article-title":"Hyperinsulinemia and risk of Alzheimer disease","volume":"63","author":"Luchsinger","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/01.WNL.0000129989.28404.9B","article-title":"Fasting insulin and incident dementia in an elderly population of Japanese-American men","volume":"63","author":"Peila","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"key":"10.3233\/JAD-150493_ref28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.tpj.6500383","article-title":"Genetic discoveries as the basis of personalized therapy: Rosiglitazone treatment of Alzheimer\u2019s disease","volume":"6","author":"Hsueh","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.3233\/JAD-150493_ref29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-150493_ref30","doi-asserted-by":"crossref","unstructured":"(1998) Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158, 1855\u20131867.","DOI":"10.1001\/archinte.158.17.1855"},{"key":"10.3233\/JAD-150493_ref31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.61.1.59","article-title":"Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials","volume":"61","author":"Grundman","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref32","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-133-1-200007040-00016","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"133","author":"DeFronzo","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-150493_ref34","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes\u20132010. Diabetes Care 33 (Suppl 1), S11\u2013S61.","DOI":"10.2337\/dc10-S011"},{"key":"10.3233\/JAD-150493_ref35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2105\/AJPH.90.3.340","article-title":"New NHLBI clinical guidelines for obesity and overweight: Will they promote health?","volume":"90","author":"Strawbridge","year":"2000","journal-title":"Am J Public Health"},{"key":"10.3233\/JAD-150493_ref36","first-page":"S14","article-title":"II clinical trial of metformin in amnestic MCI: Rationale, methods, and barriers and enablers of successful recruitment","volume":"15","author":"Perez","year":"2011","journal-title":"J Nutr Health Aging"},{"key":"10.3233\/JAD-150493_ref37","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1046\/j.1532-5415.2003.51455.x","article-title":"Screening for dementia by telephone using the memory impairment screen","volume":"51","author":"Lipton","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-150493_ref38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref39","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","article-title":"Evaluating storage, retention, and retrieval in disordered memory and learning","volume":"24","author":"Buschke","year":"1974","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.3233\/JAD-150493_ref40","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jalz.2012.05.2187","article-title":"The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials","volume":"9","author":"Raghavan","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-150493_ref41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/archneur.62.11.1739","article-title":"Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community","volume":"62","author":"Manly","year":"2005","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneur.1992.00530290035009","article-title":"Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education","volume":"49","author":"Stern","year":"1992","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"10.3233\/JAD-150493_ref43","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer\u2019s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-150493_ref44","volume-title":"Wechsler Memory Scale-revised manual","author":"Weschler","year":"1987"},{"key":"10.3233\/JAD-150493_ref45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-150493_ref46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JAD-150493_ref47","volume-title":"Manual for the adult Weschler intelligence scale-Revised","author":"Weschler","year":"1981"},{"key":"10.3233\/JAD-150493_ref48","first-page":"1238","article-title":"A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET","volume":"36","author":"Minoshima","year":"1995","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-150493_ref49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer\u2019s disease treatment studies","volume":"159","author":"Alexander","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-150493_ref50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/nimg.1998.0381","article-title":"Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative andnonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping","volume":"9","author":"Signorini","year":"1999","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-150493_ref51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/diacare.26.4.977","article-title":"Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program","volume":"26","author":"The Diabetes Prevention Program Research, Group","year":"2003","journal-title":"Diabetes Care"},{"key":"10.3233\/JAD-150493_ref52","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: Implications for sequence of pathological events in Alzheimer\u2019s disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.3233\/JAD-150493_ref53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-008-0833-y","article-title":"Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer\u2019s disease","volume":"35","author":"Li","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-150493_ref54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11064-006-9207-7","article-title":"Relation of plasma homocysteine to plasma amyloid beta levels","volume":"32","author":"Luchsinger","year":"2007","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-150493_ref55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.transproceed.2005.11.090","article-title":"Soluble HLA class I molecules exert differentiated influence on renal graft condition","volume":"38","author":"Chudyk","year":"2006","journal-title":"Transplant Proc"},{"key":"10.3233\/JAD-150493_ref56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/humu.10060","article-title":"Miniaturized sealed-tube allele-specific PCR","volume":"19","author":"Hawkins","year":"2002","journal-title":"Hum Mutat"},{"key":"10.3233\/JAD-150493_ref57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gr.157901","article-title":"High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers","volume":"11","author":"Myakishev","year":"2001","journal-title":"Genome Res"},{"key":"10.3233\/JAD-150493_ref58","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(03)00735-5","article-title":"Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance","volume":"92","author":"Tuan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.3233\/JAD-150493_ref59","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ahj.2004.04.028","article-title":"High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit","volume":"148","author":"Ridker","year":"2004","journal-title":"Am Heart J"},{"key":"10.3233\/JAD-150493_ref60","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1301\/nr.2007.dec.S253-S259","article-title":"Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity","volume":"65","author":"Ridker","year":"2007","journal-title":"Nutr Rev"},{"key":"10.3233\/JAD-150493_ref61","first-page":"87","article-title":"Association of C-reactive protein with cognitive impairment","volume":"67","author":"Noble","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150493_ref62","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"10.3233\/JAD-150493_ref63","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref64","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"key":"10.3233\/JAD-150493_ref65","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref66","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-146-6-200703200-00015","article-title":"Trials that matter: Rosiglitazone, ramipril, and the prevention of type 2 diabetes","volume":"146","author":"Nathan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-150493_ref67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMe078117","article-title":"Rosiglitazone and cardiotoxicity \u2013weighing the evidence","volume":"357","author":"Nathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.3233\/JAD-150493_ref69","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150493_ref70","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00003495-199549050-00007","article-title":"A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus","volume":"49","author":"Dunn","year":"1995","journal-title":"Drugs"},{"key":"10.3233\/JAD-150493_ref71","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jnnp.2003.012096","article-title":"Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer\u2019s disease","volume":"75","author":"Tian","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-150493_ref72","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance","volume":"54","author":"The Diabetes Prevention Program Research, Group","year":"2005","journal-title":"Diabetes"},{"key":"10.3233\/JAD-150493_ref73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","article-title":"The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial","volume":"142","author":"Orchard","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-150493_ref74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref75","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMcp021106","article-title":"Initial management of glycemia in type 2 diabetes mellitus","volume":"347","author":"Nathan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-150493_ref76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0149-7634(01)00016-1","article-title":"Cognitive effects of insulin in the central nervous system","volume":"25","author":"Park","year":"2001","journal-title":"Neurosci Biobehav Rev"},{"key":"10.3233\/JAD-150493_ref77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.02.048","article-title":"Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer\u2019s disease","volume":"490","author":"Watson","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-150493_ref78","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-150493_ref79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.phrs.2011.11.001","article-title":"Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury","volume":"65","author":"Ishibashi","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.3233\/JAD-150493_ref80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0032-1321878","article-title":"Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression","volume":"44","author":"Ishibashi","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.3233\/JAD-150493_ref81","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1073\/pnas.0807991106","article-title":"Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer\u2019s amyloid peptides via up-regulating BACE1 transcription","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-150493_ref82","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: A population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-150493_ref83","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"key":"10.3233\/JAD-150493_ref84","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer\u2019s disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.3233\/JAD-150493_ref85","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer\u2019s-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-150493_ref86","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-150493_ref87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/jnnp-2013-305078","article-title":"Measuring cognitive change in subjects with prodromal Alzheimer\u2019s disease","volume":"85","author":"Mura","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-150493_ref88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/JGP.0b013e318209dd3a","article-title":"Practice effects predict cognitive outcome in amnestic mild cognitive impairment","volume":"19","author":"Duff","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150493_ref89","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11682-012-9166-3","article-title":"The Alzheimer\u2019s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): An expansion of the ADAS-Cog to improve responsiveness in MCI","volume":"6","author":"Skinner","year":"2012","journal-title":"Brain Imaging Behav"},{"key":"10.3233\/JAD-150493_ref90","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neurobiolaging.2012.03.006","article-title":"Estimating sample sizes for pre-dementia Alzheimer\u2019s trials based on the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"34","author":"Grill","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-150493_ref91","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma Abeta40 and Abeta42 and Alzheimer\u2019s disease: Relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-150493_ref92","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2012.09.017","article-title":"AD dementia risk in late MCI, in early MCI, and in subjective memory impairment","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-150493_ref93","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14656566.2012.705829","article-title":"Overview of metformin: Special focus on metformin extended release","volume":"13","author":"Ali","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.3233\/JAD-150493_ref94","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.3233\/JAD-150493_ref95","first-page":"637","article-title":"Clinical Dementia Rating (CDR)","volume":"24","author":"Berg","year":"1988","journal-title":"Psychopharmacol Bull"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-150493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:17Z","timestamp":1777370537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-150493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":94,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-150493","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}